Levetiracetam Ciclum Farma (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which modulates neurotransmitter release. This action stabilizes neuronal firing and decreases the hyper‑excitability that leads to seizure activity, providing seizure control across several epilepsy syndromes.

The dosage of Levetiracetam Ciclum Farma is individualized by the prescribing clinician based on the patient’s age, weight, renal function, and seizure type. The prescriber determines the appropriate starting dose and any subsequent adjustments.

Safety data for levetiracetam in pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levetiracetam offers a distinct mechanism by targeting SV2A, which differs from sodium‑channel blockers like carbamazepine. It generally has fewer drug‑enzyme interactions, a favorable tolerability profile, and does not require routine blood level monitoring, making it a convenient option for many patients.

Store the product at ambient temperature, below 25 °C, in its original container. Protect it from moisture, direct sunlight, and excessive heat to maintain stability and potency throughout its shelf life.

Levetiracetam Ciclum Farma is taken orally, usually with or without food, as directed by the prescriber. The tablets should be swallowed whole with water and not crushed or chewed unless specifically instructed.

Serious risks include severe skin reactions such as Stevens‑Johnson syndrome, mood alterations including depression or suicidal thoughts, and rare blood disorders. Patients should promptly report any rash, mood changes, or unusual symptoms to their healthcare provider.

Patients with known hypersensitivity to levetiracetam or any of its excipients should avoid the medication. Caution is also advised for individuals with severe renal impairment, as dose adjustments are required, and for those taking interacting anticonvulsants without proper monitoring.